Bio-Techne (TECH) Current Deferred Revenue (2014 - 2026)

Bio-Techne's Current Deferred Revenue history runs 13 years deep, the most recent figure standing at $40.7 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 26.13% year-over-year to $40.7 million; the TTM figure through Mar 2026 stood at $40.7 million (up 26.13% YoY), while the FY2025 annual figure was $35.3 million, up 26.39% from the prior year.
• Current Deferred Revenue was $40.7 million for Q1 2026 at Bio-Techne, up from $31.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $40.7 million in Q1 2026 to a low of $23.1 million in Q1 2022.
• Historically, Current Deferred Revenue has averaged $28.7 million across 5 years, with a median of $27.9 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue climbed 28.09% in 2023, then slipped 7.92% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $23.5 million in 2022, then advanced by 28.09% to $30.1 million in 2023, then decreased by 7.92% to $27.7 million in 2024, then rose by 11.96% to $31.0 million in 2025, then jumped by 31.16% to $40.7 million in 2026.
• The last three Current Deferred Revenue figures came in at $40.7 million (Q1 2026), $31.0 million (Q4 2025), and $30.4 million (Q3 2025), per Business Quant data.